He discusses some of the key theme of the conference including obesity, IgG, ATTR cardiomyopathy, and more.

Kevin Parker describes how Cartography has been building an antigen map over previous years.

Paul Matteis gives his take on biotech's start to the year and comments on Alnylam, Biogen, Vertex, KalVista, Denali, Acadia, and more.

Raphael Townshend describes how the company has used AI and large language models to understand the structure and function of RNA.

Daphne Koller describes the platform insitro has been building since it was founded in 2018.

David Nierengarten gives his take on biotech and discusses Blueprint Medicines, G1 Therapeutics, Y-mAbs, Fusion Pharma, and more.

Aaron Kantoff describes Scion's mission and investment strategy and shares his thoughts on the current state of biotech.

The CEO of the Pennsylvania Biotechnology Center, Hepatitis B Foundation, and Blumberg Institute talks about Pennsylvania biotech.

Dr. Grupp describes the factors that might affect access, demand, and the longevity of the launches of the new sickle cell products.

Dr. Levine highlights work being done at UPenn including a 3-day CAR with IL-18, a dual CAR targeting GBM

Jeff Marrazzo describes the strengths that Philadelphia has to make it biotech's capital of cell and gene therapy.

Bassil Dahiyat walks us through the latest advances in bi-specific antibody engineering and gives his take on L.A.'s biotech scene.

Neena Bitritto-Garg joins Analyst Thursdays and talks Prothena, Sarepta, Acadia, Compass Pathways, Neumora, Sage, and Amylyx.

Salim Syed discusses this morning’s FOREST-HCM update, Gilead’s Trodelvy news, CRISPR’s allo CAR-T pivot, and more.

Tim Opler discusses the M&A environment, IPO windown, PIPE and crossover financings, and more.

Cantor Fitzgerald biotech analyst Eric Schmidt talks about themes he thinks will work in 2024, tracking important launches, and technologies

Head of Healthcare & Life Sciences Capital Markets Johanna Grossman describes the assets that NYSE has available for biotech companies that

Michael Yee shares takeaways from last week's conference in San Francisco and highlights his top names to watch.

Patrick Nosker gives his take on today's conference news and highlights the science behind some of his firm's top holdings.

Noubar Afeyan hits on themes like partnering with pharma in earlier stages, AI, and the globalization of biotech.